Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
87.38
-0.21 (-0.24%)
Nov 15, 2024, 10:15 AM EST - Market open
Boston Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 15,911 | 14,240 | 12,682 | 11,888 | 9,913 | 10,735 | Upgrade
|
Revenue Growth (YoY) | 15.66% | 12.29% | 6.68% | 19.92% | -7.66% | 9.28% | Upgrade
|
Cost of Revenue | 4,973 | 4,391 | 4,003 | 3,760 | 3,242 | 3,103 | Upgrade
|
Gross Profit | 10,938 | 9,849 | 8,679 | 8,128 | 6,671 | 7,632 | Upgrade
|
Selling, General & Admin | 5,751 | 5,190 | 4,520 | 4,359 | 3,787 | 3,928 | Upgrade
|
Research & Development | 1,519 | 1,414 | 1,323 | 1,204 | 1,143 | 1,174 | Upgrade
|
Operating Expenses | 8,109 | 7,432 | 6,646 | 6,304 | 5,719 | 5,801 | Upgrade
|
Operating Income | 2,829 | 2,417 | 2,033 | 1,824 | 952 | 1,831 | Upgrade
|
Interest Expense | -290 | -265 | -470 | -341 | -361 | -473 | Upgrade
|
Interest & Investment Income | 94 | 22 | 10 | 4 | 3 | 30 | Upgrade
|
Currency Exchange Gain (Loss) | -22 | -41 | -31 | -27 | -32 | -35 | Upgrade
|
Other Non Operating Income (Expenses) | -38 | -16 | -14 | -7 | 6 | 1 | Upgrade
|
EBT Excluding Unusual Items | 2,573 | 2,117 | 1,528 | 1,453 | 568 | 1,354 | Upgrade
|
Merger & Restructuring Charges | -30 | -69 | -24 | -40 | -179 | -452 | Upgrade
|
Impairment of Goodwill | - | - | - | - | -73 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -55 | -59 | -1 | 250 | 383 | -30 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | -22 | 78 | - | - | Upgrade
|
Asset Writedown | -276 | -58 | -132 | -370 | -452 | -105 | Upgrade
|
Legal Settlements | - | 111 | -173 | -430 | -278 | -115 | Upgrade
|
Other Unusual Items | -11 | -58 | -35 | 136 | -49 | 35 | Upgrade
|
Pretax Income | 2,201 | 1,984 | 1,141 | 1,077 | -80 | 687 | Upgrade
|
Income Tax Expense | 414 | 393 | 443 | 36 | 2 | -4,013 | Upgrade
|
Earnings From Continuing Operations | 1,787 | 1,591 | 698 | 1,041 | -82 | 4,700 | Upgrade
|
Minority Interest in Earnings | 5 | 1 | - | - | - | - | Upgrade
|
Net Income | 1,792 | 1,592 | 698 | 1,041 | -82 | 4,700 | Upgrade
|
Preferred Dividends & Other Adjustments | -1 | 22 | 56 | 56 | 33 | - | Upgrade
|
Net Income to Common | 1,793 | 1,570 | 642 | 985 | -115 | 4,700 | Upgrade
|
Net Income Growth | 45.93% | 128.08% | -32.95% | - | - | 181.27% | Upgrade
|
Shares Outstanding (Basic) | 1,469 | 1,453 | 1,431 | 1,422 | 1,417 | 1,392 | Upgrade
|
Shares Outstanding (Diluted) | 1,483 | 1,464 | 1,440 | 1,434 | 1,417 | 1,411 | Upgrade
|
Shares Change (YoY) | 1.89% | 1.65% | 0.41% | 1.21% | 0.43% | 0.66% | Upgrade
|
EPS (Basic) | 1.22 | 1.08 | 0.45 | 0.69 | -0.08 | 3.38 | Upgrade
|
EPS (Diluted) | 1.21 | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 | Upgrade
|
EPS Growth | 47.19% | 138.42% | -34.96% | - | - | 179.83% | Upgrade
|
Free Cash Flow | 2,156 | 1,792 | 938 | 1,316 | 1,132 | 1,375 | Upgrade
|
Free Cash Flow Per Share | 1.45 | 1.22 | 0.65 | 0.92 | 0.80 | 0.97 | Upgrade
|
Gross Margin | 68.74% | 69.16% | 68.44% | 68.37% | 67.30% | 71.09% | Upgrade
|
Operating Margin | 17.78% | 16.97% | 16.03% | 15.34% | 9.60% | 17.06% | Upgrade
|
Profit Margin | 11.27% | 11.03% | 5.06% | 8.29% | -1.16% | 43.78% | Upgrade
|
Free Cash Flow Margin | 13.55% | 12.58% | 7.40% | 11.07% | 11.42% | 12.81% | Upgrade
|
EBITDA | 4,063 | 3,613 | 3,169 | 2,917 | 2,075 | 2,842 | Upgrade
|
EBITDA Margin | 25.54% | 25.37% | 24.99% | 24.54% | 20.93% | 26.47% | Upgrade
|
D&A For EBITDA | 1,234 | 1,196 | 1,136 | 1,093 | 1,123 | 1,011 | Upgrade
|
EBIT | 2,829 | 2,417 | 2,033 | 1,824 | 952 | 1,831 | Upgrade
|
EBIT Margin | 17.78% | 16.97% | 16.03% | 15.34% | 9.60% | 17.06% | Upgrade
|
Effective Tax Rate | 18.81% | 19.81% | 38.83% | 3.34% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.